RxDoctor Payments Data

Srinivasa Palnati, MD

Internal Medicine · Sun City, AZNPI 1881688992

Payments from drug & device makers

$6,814in general payments, 2019–2025

Across 357 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$666
  • GSK$580
  • Pfizer$517
  • Amgen$489
  • Abbott$460
  • Astellas Pharma US Inc$456
  • plus $4K from 44 others

What the payments were for

  • Food & beverage$6,72299%
  • Education$921%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,814 in reported general payments places this provider in the 90th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$375,340
Medicare patients
760
Services billed
4,805

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban190$227,521
OzempicSemaglutide137$176,534
JardianceEmpagliflozin56$82,640
TrulicityDulaglutide38$76,047
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$74,335
MounjaroTirzepatide56$74,235
FarxigaDapagliflozin Propanediol42$57,299
ProliaDenosumab26$44,766
XareltoRivaroxaban39$40,855
MyrbetriqMirabegron43$31,127
GemtesaVibegron19$25,879
JanuviaSitagliptin Phosphate15$23,081
JanumetSitagliptin Phos/Metformin Hcl17$22,646
Tresiba Flextouch U-100Insulin Degludec13$13,374
Levothyroxine Sodium1,054$9,800

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$517$231,809229 claims
Novo NordiskOzempic$354$176,534137 claims
Lilly USA, LLCTrulicity, Mounjaro$103$150,28294 claims
Boehringer IngelheimJardiance$275$82,64056 claims
GSKTrelegy Ellipta$580$74,33558 claims
AstraZenecaFarxiga, Nexium$268$63,59558 claims
MerckJanuvia, Janumet$151$45,72732 claims
AmgenProlia$489$44,76626 claims
Johnson & JohnsonXarelto$90$40,85539 claims
Astellas Pharma US IncMyrbetriq$456$31,12743 claims
Sumitomo Pharma America, Inc.Gemtesa$42$25,87919 claims
AbbVieSynthroid$666$4,19298 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Sun City

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →